Dr. John Cush RheumNow
2 years 5 months ago
K Kuhn et al: Altered tryptophan catabolism by microbiome may contribute to inflammatory arthritis. Tryptophan increases indole leading to ncreases in serum IL-6, TNF, and IL-1β; splenic RORγt+CD4+ T cells, & IL-23 and IL-17 production https://t.co/Bqm5ecvGR5 https://t.co/O1jCSqFICr
Infectious conditions are a significant cause of mortality in autoimmune rheumatic diseases (ARD). Among patients hospitalized with an infection, we compared in-hospital and long-term (3-year) mortality between those with and without ARD.
A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs.
Dr. John Cush RheumNow
2 years 5 months ago
The EMAs CHMP has recommended for approval Two biosimilars, Tofidence (tocilizumab) and Wezenla (ustekinumab) https://t.co/mREclYdeCk https://t.co/zQX00Ys8oH
Dr. John Cush RheumNow
2 years 5 months ago
MGH study compared 1148 acute CPPD vs 3730 controls (mean 73 yrs) found 2 fold more fractures (mostly wrist); 11.7 vs 5.5/1000 PYs (HR 1.8) in pseudogout pts (also had more steroids & OP) https://t.co/HhCV6fYubF https://t.co/3bcbvSzzPo
Dr. John Cush RheumNow
2 years 5 months ago
Substitute Measures of Inflammation (many dervied from the CBC)
https://t.co/rYBqrNH8Zo https://t.co/Fa1mC17ErJ
Dr. John Cush RheumNow
2 years 5 months ago
RECIPE Study: Non-opioid Analgesics following Total Hip Arthroplasty
Patients undergoing total hip arthroplasty using a combo of paracetamol, ibuprofen, + dexamethasone, had optimal responses with the lowest morphine consumption, & fewer adverse events.
https://t.co/PXmPGscwu3 https://t.co/2Lse0gNx70
Dr. John Cush RheumNow
2 years 5 months ago
RISE study of 700 Pegloticase users (14 mos F/U) found 18% on immunosuppressive (MTX, MMF, LEF), these had signif less PEG D/C (HR 0.52-0.69). Immunosuppressives not assoc w/ more lab abnormalities https://t.co/4ytot7HOMh https://t.co/0wrjvnZur3
Dr. John Cush RheumNow
2 years 5 months ago
PI states risk of GI Perforations (GIP) incr w/ IL-6i (1.1--2.6/1000PYs) & JAKi (~1-2/1000PY) . French Insurance pop. study of ~40K pts on JAKi or adalimumab found NO no signif difference betw JAK v ADA (IR: 2.1 vs 1.1/1000PYs; p=0.65). https://t.co/YlxiBOhNFj https://t.co/A5hMbWDXeV
In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to the relationship between interferons and lupus, which affects up to 1.5 million Americans.
Dr. John Cush RheumNow
2 years 5 months ago
NEJM: evolution of pyoderma gangrenosum skin lesions https://t.co/wE9pAZZs9L https://t.co/jTijcCvpfI
Johns Hopkins Rheumatology Fellows JHRheumFellows
2 years 5 months ago
Who is confused about what to do for #GI symptoms in #scleroderma? @TimKanieckiMD does a masterful breakdown of gut involvement for @jhrheumatology rounds. You can read further in: https://t.co/xw6EElGIWl
@ZsuzsannaM55365 would be proud!
#MentoredResearchProjects
#dysmotility https://t.co/yLVD7Vo1SJ
Donald Thomas, MD lupuscyclopedia
2 years 5 months ago
10 Lupus Tips on May 10 (World Lupus Day) by @LupusMore
https://t.co/mON5ZyTpUE
#lupus #SLE #LupusAwarenessMonth
Laurent ARNAUD Lupusreference
2 years 5 months ago
✅ Holistic #Lupus Management in 2024 👍 #LupusAwarenessMonth https://t.co/RY6AcHS9WQ
Dr. John Cush RheumNow
2 years 5 months ago
"On being a physician" - a White Coat Ceremony address by Dr. John F. Fischer from the Medical College of Georgia 2024 https://t.co/tBlT6DEddU via @YouTube
